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Abstract
Background: Our study focuses on identifying potential biomarkers for diagnosis and early detection of ovarian
cancer (OC) through the study of transcription regulation of genes affected by estrogen hormone.
Results: The results are based on a set of 323 experimentally validated OC-associated genes compiled from several
databases, and their subset controlled by estrogen. For these two gene sets we computationally determined
transcription factors (TFs) that putatively regulate transcription initiation. We ranked these TFs based on the
number of genes they are likely to control. In this way, we selected 17 top-ranked TFs as potential key regulators
and thus possible biomarkers for a set of 323 OC-associated genes. For 77 estrogen controlled genes from this set
we identified three unique TFs as potential biomarkers.
Conclusions: We introduced a new methodology to identify potential diagnostic biomarkers for OC. This report is
the first bioinformatics study that explores multiple transcriptional regulators of OC-associated genes as potential
diagnostic biomarkers in connection with estrogen responsiveness. We show that 64% of TF biomarkers identified
in our study are validated based on real-time data from microarray expression studies. As an illustration, our
method could identify CP2 that in combination with CA125 has been reported to be sensitive in diagnosing
ovarian tumors.
Background
Ovarian cancer (OC) is the leading cause of death
among gynecological malignancies and represents the
fifth leading cause of cancer-related deaths in women.
The disease is diagnosed at stage when cancer has
already metastasized beyond the ovary in approximately
70% of patients and only 30% of these patients with this
advanced-stage OC survive 5 years after initial diagnosis
[1]. This inability to detect ovarian carcinoma during
the early organ-confined stage combined with the lack
of effective therapies for advanced-stage disease contri-
butes to lethal effects of this cancer. In patients with
metastasized OC, most relapse and ultimately die due to
the development of drug resistance [2].
Early diagnosis greatly enhances the chances of suc-
cessful cancer treatment. To this date, very few early-
detection approaches have shown promise for routine
clinical use. The most commonly used marker of OC is
CA125, but it is expressed in 50-60% of patients during
early stages of the disease [3]. Several biomarkers either
individually or in combination with CA 125 have been
proposed for early-detection and screening of OC [4].
FDA recently cleared an In Vitro Diagnostic Multivariate
Index Assay (IVDMIA) i.e. OVA1 test that involves ana-
lysis of five serum biomarkers for assessing ovarian can-
cer risk in women [5]. Over the past few years it has
become increasingly evident that many molecular
changes observed in cancer cells involve deregulation of
gene expression. Understanding the underlying molecu-
lar mechanisms of gene regulation could thus be crucial
for identifying the key genes or proteins that can be
exploited as prognostic or diagnostic biomarkers in OC.
This makes transcription factors (TFs) an interesting
target for further explorati o ni nt h i sd i r e c t i o n[ 6 ] .T h e
majority of oncogenic signaling pathways converge on
sets of TFs that ultimately control gene expression pat-
terns characteristic for tumor formation and progres-
sion, as well as metastasis. Since many of these TFs are
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siological conditions and their expression and activities
are tightly regulated, these TFs represent highly desir-
able and logical points of therapeutic interference in
cancer development, progression and prognostication
[7-9], markers for cancer [10], potential prognostic mar-
kers [7,11] and targets for drug therapy [12]. More
recently the use of TFs as markers for the disease itself
has been reported and they have been detected in the
blood [10,13,14]. Another study [7] investigated the role
of survival-related profile, pathways, and TFs in OC.
The study reported that 13 out of 111 TFs were asso-
ciated with overall survival in patients with OC. Since
hormones also play an important role in gene expres-
sion [15] and are implicated in many cancers [16-19], it
also becomes important to study the effects of hor-
mones in cancers. It is documented that high levels of
expression of estrogen receptor alpha (ERa) has been
observed in many OCs and OC cells are growth respon-
sive to both estrogen and anti-estrogens [20]. This
emphasizes that ERa could have therapeutic potential
for at least a sub-group of OC patients [21-23]. The
hormone replacement therapy has also been linked with
an increased risk of OC [24]. Recently, the prognostic
value of estrogen receptors (ERs) for OC has been
emphasized [25]. It is worth noting that the studies
explaining the role of hormones in OC are few and
require elaborative investigations [26]. Therefore, in the
present study we focus on transcription regulation and
also estrogen control of genes in OC. The question we
addressed is to identify potential diagnostic TFs impli-
cated in regulating the expression of OC genes that in
turn could potentially be regulated by estrogen hor-
mone. We aimed at linking hormone induction to over-
all transcription regulation of genes in cancer cells. We
anticipate that the target pool of biomarkers could be
revealed by studying specific signatures within the hor-
mone dependent regulatory gene networks.
Computational approaches are a pragmatic and inex-
pensive way to identify the key regulatory genes, hence,
pinpointing the targets for experimental validation. For
example, bioinformatics methods were employed to
identify candidate genes for discriminating different
tumoral histotypes for OC, lung and breast cancer diag-
nostics [27]. In general, steroid hormones are recognized
initially by hormone receptors that then bind to Hor-
mone-Response Elements (HREs) on DNA and control
the expression of some of their target genes. This can
be used to predict a part of genes that are potentially
controlled by hormone receptors under the condition
that promoters of these genes contain HREs. Thus, the
identification and characterization of HREs is critical for
our understanding of hormone driven gene expression
and regulation in various cancers and computational
methods could be of great help [28-31]. To contribute
to the discovery of diagnostic biomarkers for OC we
developed a computational method which, in combina-
tion with the manual curation of the literature informa-
tion, helped us to identify the potential biomarkers that
could regulate a set of genes implicated in OC. Our ana-
lysis singles out several such TFs. The previous efforts
that used the bioinformatics approach to identify a TF,
E2F5, and then experimentally confirm it as a potential
diagnostic biomarker for OC were made by our group
[6]. Our current study is, to the best of our knowledge,
the only one that targets through purely bioinformatics
approach, transcriptional regulators of OC-associated
genes as potential biomarkers in relation to estrogen
responsiveness.
Results and Discussion
This study identified potential biomarkers important for
overall transcriptional regulation of OC genes and speci-
fically for a sub-group of OC genes controlled by estro-
gen. To identify genes controlled by estrogen, two
approaches were used: (a) prediction of estrogen
response elements (EREs) on the promoters of OC
genes, and (b) finding the experimental evidence for
estrogen control in published databases. The presence
of EREs in a promoter suggests that ERE sites may be
used by activated hormone receptors and consequently
could affect gene expression. The EREs were predicted
on 246 promoters corresponding to 65 genes. Out of
these 65 genes, 11 genes had experimental evidence of
being responsive to estrogen as these genes were found
in either KBERG [32] or ERTargetDB [33] databases. In
the dataset, there were 258 genes lacking predicted
EREs in their promoters. Out of these 258 genes, 66
were under estrogen control as supported by KBERG or
ERTargetDB. We split the genes into four groups that
were analyzed further. These four groups were:
G r o u p1 )g e n e sw i t hp r e d i c t e dE R E sa n dw i t he x p e r i -
mental evidence of estrogen responsiveness (11 genes);
Group 2) genes with predicted EREs with no experi-
mental evidence of estrogen responsiveness (54 genes);
Group 3) genes without ERE predictions but with
experimental evidence of estrogen responsiveness (66
genes); and
G r o u p4 )g e n e sw i t h o u tE R Ep r e d i c t i o n sa n dn o
experimental evidence of estrogen responsiveness (192
genes).
It is to be emphasized here that ERs can also affect
gene expression by forming protein-protein complexes
with other TFs such as activator protein-1 (AP-1), Sp1
family TFs, nerve factor-ß (NF-ß), etc. These complexes
in turn can bind to the genes’ promoters and regulate
gene expression. Through these ERE-independent path-
ways, ERs can control the expression of many genes,
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ment of the full ERE. Therefore, the EREs, though good
indicators that genes may be controlled by estrogen, are
not essential for responsiveness to estrogen. On its own,
t h ep r e s e n c eo fE R E si nt h ep r o m o t e rr e g i o no fag e n e
is not conclusive evidence of the hormonal control of
expression of that gene. However, the presence of EREs
in a promoter suggests that such ERE sites could be
used by activated hormone receptors and consequently
could affect gene expression.
(a) Functional analysis of target genes
The GO analysis was performed as described in Material
and Methods. The results for each group are discussed
below:
Group 1: This group contains genes with predicted
EREs and with experimental evidence of estrogen
responsiveness. This group contains only 11 genes (3%
of total 323 genes under study). The GO analyses of
these genes show that 45% of genes in group 1 had
kinase activity (additional file 1).
Group 2: The genes in this group (17% of 323 genes)
have predicted EREs but they lack experimental evi-
dence of being responsive to estrogen. It may be
assumed that these genes might be under the control of
estrogen hormone but this observation has not been
conclusively demonstrated or supported by literature.
GO analyses revealed that 24% (13 out of 54) had kinase
activity and 26% of genes were involved in nucleotide
binding (additional file 1).
Group 3: All the 66 genes (20%) in this group have no
predicted EREs but have experimental evidence of being
estrogen responsive. The genes in this group were
mainly involved in organ development (32%), positive
regulation of cellular processes (29%) and intracellular
signaling cascade (26%). Onl yt h r e e( 5 % )w e r ei n v o l v e d
in regulation of I-kappaB kinase/NF-kappaB cascade
(additional file 1).
Group 4: The genes in this group contain no ERE predic-
tions, and have no experimental evidence in support of an
estrogen response and constitute approximately 60% (192
of 323) of the total number of genes under study. Most of
these genes (38%) were involved in cellular protein meta-
bolic process. Some of the genes in this group (23%) were
part of cell surface receptor linked signal transduction,
while others (21%) had kinase activity (additional file 1).
(b) Analysis of TF binding sites (TFBSs)
The gene groups were then subjected to TFBS analysis
as explained in Materials and Methods. The results of
TFBS analysis are summarized in following sections:
(i) Distribution of TFBSs in promoters of OC genes
We predicted 9246 TFBSs corresponding to 299 TFs
using 522 TRANSFAC matrices. The distribution of all
predicted TFBSs in OC genes is presented in Figure 1.
This figure shows the distribution of TFBSs using the
Gaussian-kernel density estimator implemented in the R
statistical environment under the function name, “plot.
density"; the greatest density is just upstream of tran-
scription start sites (TSSs).
(ii) Distribution of TFBSs and EREs in promoters of genes
that contain predicted EREs
It has been demonstrated in the literature [34] that dis-
tance between ERE and TFBS is crucial for transcription
of the gene. Some studies also suggest that most of the
ERE effects are at very large distance from TSSs of
g e n e st h e yr e g u l a t e[ 3 5 ] .T h ea c t i v i t i e so ft h ed o w n -
stream promoter of vitellogenin gene A1 are shown to
be controlled by EREs located 330 bases upstream of
the TSS and it is speculated that EREs located up to 1.5
kb downstream can also control the promoter [36]. The
distribution of distances between TFBSs and EREs
within the promoters of OC genes that have predicted
EREs is presented in Figure 2. For this analysis we
pooled the results of group 1 and group 3 genes as both
these groups had genes experimentally validated to be
estrogen responsive. We found 260 TFs had TFBSs
completely overlapping with EREs, whereas 299 TFs had
TFBSs predicted at a maximum distance of 95 bases
from predicted EREs. The detailed results are provided
(additional file 2). Most of the TFs having TFBSs within
a distance of 95 bases from predicted EREs were
involved in cancer related biological processes. This sug-
gests that the closeness of ERE to some other TFBSs
implicated in our analysis could synergistically function
in OC.
(iii) Identification of TFs unique to groups of genes
The enriched TFBSs (i.e. ORI > = 2, Materials and
Methods) were used for network construction. The TFs
potentially regulating maximum number of genes in
each group were identified. The TFs were ranked based
on the number of genes they regulate as demonstrated
v i aT F B S so nt h ep r o m o t e r so ft h eg e n e s .W eu s e da
cut-off of 80
th percentile to identify the TFs regulating
maximum number of genes in a group. Any TF having
TFBSs in genes below 80
th percentile were not included
in further analysis. These steps lead us to identify TFs
unique to sets of genes in each group (Figure 3). Figure
3 also show that multiple TFs may regulate set of genes
in different groups thus highlighting the TF families that
could be of relevance for further investigations in OC.
Using the cut-off as mentioned above, we identified 18
TFs having TFBSs in promoters of 11 genes in group 1.
The 54 genes in group 2 contained TFBSs for 31 TFs.
In group 3, we found TFBSs for 23 TFs in promoters of
66 genes. For group 4, we identified TFBSs for 31 TFs
in promoters of 192 genes. We then combined groups 1
and 3 because the genes in these groups were found
Kaur et al. BMC Systems Biology 2011, 5:144
http://www.biomedcentral.com/1752-0509/5/144
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group we refer to as ‘experimentally controlled genes’.
We found that there were 17 TFs common to both gene
groups 1 and 3, with only one TF unique to group 1
and six TFs unique to group 3 (additional file 3). Thus,
we found 24 TFs that have TFBSs on the promoters of
experimentally controlled genes only. The comparison
of these 24 TFs with group 2 (group of genes containing
Figure 1 Distribution of all predicted TFBSs in OC genes. X-axis: distance in nucleotides from TFBS relative to TSS. Y-axis: estimated density
of TFBSs as calculated by a Gaussian-kernel density function implemented in the R-statistical environment as “plot.density"; the distances of all
TFBSs from the TSS are distributed across 512 points and convolved using a Gaussian kernel.
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control by estrogen) revealed that there were 19 TFs
common with the experimentally controlled genes, and
12 TFs unique to group 2 (additional file 4). Similar
comparison of TFs for experimentally controlled genes
with group 4 revealed 20 common TFs and 11 unique
TFs for group 4 (additional file 5).
The above analysis suggests that combinations of TFs
could regulate different sets of genes (Figure 3). We pro-
pose that the genes in group 2 can be considered as new
targets for experimental evaluation of estrogen control.
This proposition is based on the presence of predicted
EREs in promoters of these genes. The presence of EREs in
promoters of genes does not establish that the genes are
under estrogen control, however, the ERE predictions open
ap o s s i b i l i t yt h a tt h e s eg e n e sm a yb eu n d e rs u c hac o n t r o l .
(iv) Identification of potential markers for 323 OC genes
We propose that the TFs regulating a maximum num-
ber of OC genes can be regarded as potential candidates
for biomarkers for OC. This is based on the concept
that such TFs are the drivers of the potential deregula-
tion of genes in OC, and thus are relevant for use as
biomarkers. To identify potential candidates, we ranked
TFs with regards to the number of genes that have
TFBSs for a particular TF (see additional file 6 for list of
all ranked TFs). The ranking produced a list of 17 TFs
(Table 1) each potentially regulating more than 200 OC
genes. Top ranked three TFs (entrez ID 5079, 7020 and
1385) had TFBSs in promoters of 289, 268 and 255
genes, respectively. The top ranked TF (PAX-5) belongs
to a family of paired box TFs. The protein product of
this gene is a B-cell lineage specific activator and has
been identified as a marker for the discrimination of
low- to intermediate-grade pulmonary neuroendocrine
carcinomas from high-grade with 100% specificity and
79% sensitivity in surgical specimens [37] and for diag-
nosis of undifferentiated malignant neoplasms [38]. The
TF ranked at position two in the list (entrez ID 7020) is
AP-2 and regulates the expression of amyloid precursor
protein in oral squamous cell carcinomas [39]. It has
also been linked with breast cancer [40]. The third
ranked TF (entrez ID 7546) is zinc finger protein (ZIC2)
and has been found to be differentially expressed in
endometrial cancers with lymph node metastasis [41]
and has even been patented as a small-cell lung cancer
associated antigen (US Patent 7314721, issued on Janu-
ary 1, 2008, http://www.patentstorm.us/patents/
7314721/fulltext.html.
(v) Identification of potential markers for estrogen
regulated genes
After identifying TFs potentially regulating a maximum
number of OC genes, we looked for TFs uniquely
Figure 2 Histogram and cumulative plot of distances between TFBSs and EREs in OC promoters. X-axis: distance in nucleotides between
TFBSs and its’ closest ERE; maximum distance is limited to the size of promoters (1200 nt); frequencies of TFBSs for selected percentiles are
given. Y-axis (left, histogram): frequency of TFBSs per 50 nucleotides (24 bins); the 20th percentile is highlight blue for convenience. Y-axis (right,
dot-plot): cumulative frequency of TFBSs.
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For the ‘experimentally controlled genes’,w ei d e n t i f i e d
17 top ranked TFs (Table 1). This group has three
unique TFs ranked 15, 16 and 17, while others were
common with the previous ranked list of TFs (for all
categories combined). The TF ranked at position 15 is
CP2 (entrez ID 7024), which has been targeted as a
diagnostic marker for ovarian carcinoma [42]. The com-
bination of CA125 with CP2 has been reported to be
sensitive in diagnosing non-mucinous ovarian tumors
[43]. The TFs ranked 16 and 17 in the list are Sp2
(entrez ID 668) and Sp4 (entrez ID 6671), respectively.
The PubMed search using keywords “Sp4 ovarian can-
cer” retrieved only one abstract related to the study that
tested new analogues of a natural antibiotic ‘Mithramy-
cin’ as inhibitors of Sp1-dependent transcription in OC
xenografts [44]. Therefore, we propose that Sp4 can be
investigated as a potential new gene or marker for OC.
Another observation is that the family of Sp TFs might
have an important role to play in OC. Sp3 and Sp4 are
involved in estrogen mediated gene expression in MCF-
7 breast cancer cells [45]. Sp3 (entrez ID 6670) has been
shown to control the expression of PTEN (phosphatase
and tensin homolog deleted on chromosome 10) in
ovarian carcinomas [46]. The proximal binding of Sp1
to the TSS has been demonstrated to be a requirement
for positive interactions with the ER to enhance tran-
scription and also to stabilize weak interactions of ER
[47]. Three TFs (TFCP2, SP2 and SP4) unique to estro-
gen controlled group can be tested as specific biomar-
kers for the sub-group of patients that are influenced by
estrogen hormones.
The analysis presented above has enabled us to iden-
tify potential biomarkers that putatively regulate tran-
scription of a group of OC-associated genes. The results
presented here can be justified by the fact that the ana-
lysis could identify some of the known biomarkers (cur-
rently under investigation), such as CP2 and ZIC2. The
study has identified unique potential biomarkers for a
sub-group of genes that are known to be under estrogen
control.
(c) Preliminary validation of biomarkers using publically
available data
To see if the TFs identified in the current study have
functional roles and the potential to be used as diagnos-
tic biomarkers during early and advanced stages of OC,
we looked at genes specifically (over-expressed) as
represented in microarray analysis at different stages of
ovarian serous adenocarcinoma and metastatic ovarian
serous papillary adenocarcinoma tissue samples [48].
For identifying the genes and potential TFs associated
with these genes we used data from 24 non-metastatic
ovarian cancer tissue samples against 3 metastatic
Figure 3 Heat-map showing combinations of TFs regulating
different sets of genes. Blue blocks across the groups (columns)
indicate that several TFs (rows) may potentially regulate genes in
different groups.
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gene expression database) CleanEx (Microarray data-
base) http://www.cleanex.isb-sib.ch/index.html[49] using
dataset number AFFY004 [50]. The primary data was
used in dataset number AFFY004 was taken from [48]
and the details of primary data have been summarized
(additional file 7). We could identify three TFs (ZIC2,
E2F4 and TFCP2) in this dataset of over-expressed
g e n e si nO C .T F ss u c ha sE2F1, E2F3, TFAP2A, VDR,
TFAP2G, SP3, ZNF42, CREB1 and ELK1 were found to
be over-expressed by > = 1.5 folds in OC datasets ana-
lyzed in Oncomine http://www.oncomine.org/[51]. Our
study has shown that 65% of the TFs regulating genes
in a full set of 323 OC genes and 47% of the TFs regu-
lating estrogen controlled sub-set of genes of our predi-
cation set could be identified in real-time data from
published microarray expression studies (Table 2). This
analysis shows that the expression of a number of the
TFs identified in the present study are affected in OC
and these TFs may have the potential to be used as bio-
markers. By definition, a biomarker is useful if it can
detect the disease in early stages in a patient as com-
pared to a healthy individual. To study this, we per-
formed an analysis based on the expression profiles
available in Oncomine targeting ‘Ovarian serous adeno-
carcinoma’ which is the most common form of the OC
[52-54]. We could identify T F A P 2 A ,V D R ,T F A P 2 Gand
E2F3 as over-expressing genes in at least one of the
three datasets we studied (Table 3). The expression of
CA125 (a known biomarker of OC) was not identified in
one of the datasets under investigation [52].
T h en e x ts t e po ft h ei n v e s t i g a t i o ni n v o l v e di n - d e p t h
analysis of expression of above TFs at different stages of
OC. For this, we compared the expression levels of
genes in cancerous tissues categorized as stage IA, IC
and IIIC [54]. Figure 4 explains that the expression of
T F A P 2 A ,V D R ,T F A P 2 Gand E2F3 genes is higher in
early stages (stages IA and IC) as well as advanced stage
(IIIC) of the OC as compared to the normal tissue. The
same applies to the gene expression levels of CA125.
This analysis clearly shows that the proposed TFs can
be tested as diagnostic biomarkers for OC in detailed
laboratory investigations. Other important information
linked to some of the TFs that are proposed as biomar-
kers is their detectable expression in blood. For exam-
ple, VDR [55], E2F3 [56] and CREB1 [57] can be easily
detected in the blood and blood-based diagnostic assays
can be easily developed to measure these TFs if vali-
dated as biomarkers of OC. Further experimental inves-
tigations can also focus on establishing a link between
blood concentration of biomarkers and pathological
state of the ovary in OC.
Since the biomarkers identified were found to be pro-
mising we further looked at the pathways involved/asso-
ciated with the 17 TFs. The current data demonstrates
that the TFs identified as biomarkers are associated with
Table 1 Rankings of TFs (potential biomarkers) for complete gene set of 323 OC genes and for the ‘experimental
group’
Ranked TFs for 323 genes Ranked TFs for Experimental group
TF_ID TF_symbol Number of Gene Targets
(out-degree)
Ranks TF_ID TF_symbol Number of Gene Targets
(out-degree)
Ranks
5079 PAX5 289 1 5079 PAX5 68 1
7020 TFAP2A 268 2 7020 TFAP2A 60 2
1385 CREB1 255 3 7546 ZIC2 60 3
7546 ZIC2 253 4 1869 E2F1 57 4
7421 VDR 249 5 51385 ZNF589 55 5
1869 E2F1 248 6 7027 TFDP1 54 6
7022 TFAP2G 246 7 1871 E2F3 54 7
7027 TFDP1 245 8 7421 VDR 54 8
1874 E2F4 245 9 1874 E2F4 54 9
1871 E2F3 245 10 7021 TFAP2B 52 10
7021 TFAP2B 242 11 6670 SP3 52 11
2033 EP300 223 12 2033 EP300 52 12
6670 SP3 222 13 6667 SP1 48 13
6667 SP1 216 14 2002 ELK1 48 14
51385 ZNF589 216 15 7024 TFCP2 42 15
7593 ZNF42 214 16 6668 SP2 40 16
2002 ELK1 210 17 6671 SP4 40 17
TFs unique to both groups are shown in bold italics.
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Page 7 of 13cell cycle and cell signaling pathways that were known
to have a significant role in affecting cancer at the initia-
tion stage as well as metastatic spread (additional files 8
and 9). Functional categorization as identified using
Gene/Gene Set overlap matrix with 17 TFs identified as
biomarkers for full set of OC genes (additional file 8)
showed overlap which were prominent for cell cycle
associated TFs based on data from E2F1, E2F3-4 and
TFDP-1 genes. Estrogen- controlled sub-set of OC
genes were also found to be under the influence of cell
cycle associated TFs (additional file 9). Overlap pattern
indicates that TFs associated with G1 to S phase transi-
tion were found to be mostly affected. Transcription fac-
tors DP-1 and E2F1 showed similar overlap patterns in
the gene sets since TFDP-1 encodes a member of a
family of transcription factors that heterodimerize with
E2F proteins to enhance their DNA-binding activity and
promote transcription from E2F target genes.
We propose that the TFs identified as biomarkers in
the current study may have a prominent role associated
with genes involved in progression of OC. Our previous
study has identified E2F5 (a member of E2F family of
TFs) as a potential marker for detecting the malignancy
associated with OC [6].
(d) Physiological significance of predicted TFs
Here we describe the significance of TFs identified in
our current study and relevance of these TFs to OC as
reported by recent studies. There is growing evidence
that deregulation of cell cycle associated transcription
factors of E2F family (E2F1 to E2F8) is causatively
involved in the patho-physiology of various tumors.
Proliferation-promoting E2F transcription factors, E2F1
and especially E2F2 play a pivotal role in tumor biology
of OC and may be candidates for specific therapeutic
targets [58]. In the same study, authors demonstrate
higher expression of E2F family of TFs in 77 ovarian
cancer samples except E2F6. They also suggested that
expression levels of E2F1 and E2F2 are associated with
highly malignant and fast growing tumors. Deregulation
of both proliferation-promoting and proliferation-inhi-
biting E2F TFs and their cross-talk were reported to
influence the clinical outcome Therefore; appearance of
three members of E2F family in our top ranked list also
warrants further investigations to explore biomarker
potential of these TFs. CREB1 is another TF identified
in the current study is associated with MMP-2 tran-
scription, which is involved in pro-metastatic function
along with TG-2. EP-300 protein is a histone acetyl-
transferase and regulates transcription via chromatin
remodeling. It is found that this protein regulates
important cellular processes such as cell proliferation
and differentiation. The putative tumour suppressor
gene EP300 is located on the region 22q13 that shows
frequent loss of heterozygosity (LOH) in colon, breast
and ovarian cancers. In epithelial cancers, EP300 is
mutated and provide the evidence that it behaves as a
classical tumor-suppressor gene [59]. Higher immunor-
eactivity of vitamin D receptor (VDR) was found in
breast, ovarian and cervical carcinomas as compared to
normal corresponding tissues [60]. Recently, the VDR
polymorphism FokI was shown to be associated with
susceptibility to OC. These results suggest that the VDR
polymorphisms from the FokI genotype may be
Table 2 Validation of biomarkers based on over-expression in published OC microarray datasets available in
databases such as CleanEx and Oncomine
TFs regulating all 323 genes TFs regulating Estrogen controlled sub-set of genes
Out of top ranked 17 Out of top ranked 17
CleanEX 1 2
Oncomine Fold change > = 2 Fold change > = 1.5 Fold change > = 2 Fold change > = 1.5
TFs found 8 10 6 6
Total over-expressed TFs 9 11 8 8
Table 3 The average fold-change in expression of TFs identified as potential biomarkers in the present study and CA
125 (a known OC biomarker) in ovarian serous adenocarcinoma tissues samples in comparison to normal tissue based
on three OC pre-analyzed datasets available in Oncomine
Biomarkers Lu et al., 2004 [54] Hendrix et al., 2006 [53] Adib et al., 2004 [52]
TFAP2A 1.99 1.57 1.99
VDR 1.66 1.21 1.22
TFAP2G 1.33 1.85 2.18
E2F3 1.84 1.18 2.65
CA 125 3.33 2.97 –
The values in the table represent the fold-change of expression of genes with p-values < 0.05 and the gene ranks in top 10% (pre-calculated in Oncomine).
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EOC [61]. The PAX5 gene belongs to the paired box
(PAX) family of transcription factors. PAX5 has been
reported to be present in ovarian tumor tissues and
plasma [62]. Elk-1 has been associated with OC progres-
sion [63].
One should observe the following limitations of our
methods. We have several constraining factors involved.
First, we limited consideration of computational analysis
of transcription regulation to promoters of limited size
proximal to 5’ gene ends. While there is no method to
accurately pinpoint boundaries of promoter regions, we
used 1000 bp upstream and 200 bp downstream of TSS
as an approximation of the actual promoters. Second, a
lot of gene control is exerted from the remote control
regions such as enhancers and silencers. Since we had
no means to determine these regions for individual
genes we did not consider such regulatory effects.
Thirdly, we limited our consideration to TFs that fall
above 80
th percentile regarding the number of genes
they potentially regulate in OC gene set we considered.
Finally, the set of genes implicated in OC that we used
is by no means complete. However, in spite all these
practical odds, the method produced results that are in
high concordance with the known biological facts (a
number of the top ranked TF are either already known
diagnostic markers of represent previously proposed
markers for diagnosis of OC) and also implies some of
the new diagnostic markers for OC.
Conclusions
The analysis presented here has generated potential
molecular targets for evaluation as possible players in
the causation or characterization of OC. The ranked
lists of TFs can be used to prioritize putative biomarkers
based on their potential to regulate a large number of
genes implicated in OC. The analysis shown here has
provided deeper insights into the transcriptional regula-
tion of many genes involved in OC. We highlight that
this is an understudied field and the use of bioinfor-
matics tools could enhance our insights into the under-
lying genetic mechanism of OC. This study has
provided a list of potential target genes that could be
tested in the laboratory and ultimately be targets for
therapeutic treatments.
Methods
Outline of methodology
The study identified several genetic targets for evalua-
tion as potential diagnostic markers of OC. The promo-
ters of 323 genes implicated in OC [64] were screened
for EREs (estrogen response elements). To identify the
genes experimentally validated as estrogen responsive,
we cross-checked against two databases of documented
estrogen-responsive genes, namely KBERG [32] and
ERTargetDB [33], neither of which is comprehensive.
We divided the genes into four groups: 1) those having
predicted EREs and experimental evidence of estrogen
control; 2) have predicted EREs but no experimental evi-
d e n c eo fe s t r o g e nc o n t r o l ,3 )h a v en op r e d i c t e dE R E s
but have experimental evidence of estrogen control, and
4) neither predicted EREs nor experimental evidence of
estrogen control. We then predicted TFBSs (Transcrip-
tion factor binding sites) on the promoters of OC genes
so as to provide a link between genes and TFs that reg-
ulate them. For this purpose the Transfac Professional
database ver. 11.4 [65] was used. The TFBSs were
mapped to the promoters of OC genes using the Match
program [66] of the Transfac suite. The enrichment of
the mapped TFBSs in the target promoter set relative to
a background set was determined. The enriched TFBSs
were associated with TFs that are predicted to bind
them. In this way we established a link between the tar-
get genes and the TFs that regulate their expression.
This data was used to reconstruct parts of the transcrip-
tion regulatory networks of relevance to OC. These net-
works were analyzed to identify crucial regulators of
gene expression, opening the way to identify potential
biomarkers that characterize OC gene transcription.
Identification of genes implicated in OC
The genes implicated in OC were determined as follows.
Initially a list of 900 genes was collected from available
online resources like Cancer Gene Census [67]http://
www.sanger.ac.uk/genetics/CGP/Census/, GeneCards
[68]http://www.genecards.org/index.shtml, SymAtlas
[69], OMIM [70] (Online Mendelian Inheritance in
Figure 4 The comparison of the expression levels of TFs
identified as potential biomarkers in the present study and CA
125 (a known OC biomarker) in randomly chosen ovarian
serous adenocarcinoma tissue samples categorized at stages
IA, IC and IIIC in comparison to normal tissue based on OC
pre-analyzed dataset of study by Lu et al., 2004 [54]available in
Oncomine.
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scope Database [71]http://ovary.stanford.edu, Entrez Gene
[72]http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene and
GenAtlas [73]http://www.genatlas.org/. This list was
reduced to 379 by biologists after carefully going through
the relevant literature. The genes included in the study
were filtered through a strict criterion that the gene
expression must be experimentally confirmed in either
OC tissue using one of the techniques such as: RT-PCR,
immunohistochemistry, western blotting or FISH (Fluores-
cent In Situ Hybridization). If a gene is documented as
having an OC linked SNP, it was also included. The collec-
tion of these 379 genes can be explored using DDOC data-
base http://apps.sanbi.ac.za/ddoc/[64].
Promoter sets
The promoter sequences determined as a region cover-
ing [-1000, +200] relative to the transcription start sites
(TSS) at the 5’ ends of genes were extracted from the
Fantom3 dataset [74,75]. The promoters were extracted
for 323 Entrez IDs corresponding to the OC genes. As a
background set, we used a set of selected 11,000
sequences of length 1200 bases from human genome.
Prediction of Estrogen Response Elements (EREs)
The tool Dragon ERE Finder [76] version 6.0 http://
apps.sanbi.ac.za/ere/index.php was used to predict the
EREs on the promoters.
Matching to genes from KBERG database
The OC genes were cross-checked against all the 1516
experimentally confirmed estrogen-responsive genes in
the KBERG database [32].
Matching to genes in ERTargetDB database
The OC genes were cross-checked against the ERTar-
getDB [33], http://bioinformatics.wistar.upenn.edu/
ERTargetDB, which contains:- (a) 40 genes with 48
experimentally verified ERE direct binding sites and 11
experimentally verified ERE tethering sites; (b) 42 genes
identified via ChIP-on-chip assay for estrogen binding
(c) 355 genes from gene expression microarrays; (d)
2659 computationally predicted genes.
Transcription Factor binding sites (TFBSs) mapping
TFBSs were mapped to promoter sequences using all
mammalian matrix models of TFBSs contained in the
TRANSFAC Professional database v.11.4 [65]. For this
purpose, we used the Match program with a minFP pro-
file for the threshold of the matrix models since the
minFP profile contains the optimized threshold values
for the core and matrix scores [66] that provide mini-
mum presence of false positive predictions in the pre-
dicted TFBS set.
Enrichment of TFBSs patterns and edge identification
Enrichment of TFBSs found in the target set was deter-
m i n e du s i n gt h em e t h o df r o m[ 7 7 , 7 8 ] .T h em a p p e d
TFBSs were ranked based on their over-representation
index (ORI) [77] and those that were sufficiently
enriched (ORI > = 2, as determined by [77]) were used
for further analysis. This step produced links between
the target genes and TFs that regulate their expression
and represent an edge for network reconstruction.
Network reconstruction and identification of biomarkers
The genes were clustered again based on the promoter
content (presence of TFBSs) and this allowed us to iden-
tify the network of genes potentially regulated by indivi-
dual TFs or their combinations. The identified TFs were
ranked based on the number of genes they regulate above
80
th percentile. Finally, a list of ranked TFs was generated.
Functional and pathway analyses of network genes
After identification of networks of genes, next step was
to classify these genes based upon their functional prop-
erties. We used the existing gene ontology (GO) annota-
tion [79] information for the genes. GO term analysis
was performed for all the genes using DAVID (The
Database for Annotation, Visualization and Integrated
Discovery) version 2.0 [80] and transcripts were clus-
tered based on their functional annotations at GO level
4. This helped us to identify the functional clustering of
the genes and their role as a group in various biological
processes.
Functional analysis is very useful but provides limited
information regarding the involvement of genes in speci-
fic pathways. The gene lists were mapped to KEGG [81]
pathways using DAVID. Mapping of target genes to
KEGG helped us to identify pathways critical to the
etiology and development of OC.
The above described methodology enabled us to
identify networks of genes potentially regulated by
similar TFs and their possible roles in etiology and
development of OC, opening a way for insights that
could lead to the identification of potential diagnostic
markers of OC.
Additional material
Additional file 1: Functional analysis of all four groups of genes
using DAVID. Pathway analysis performed on all four groups of genes
using DAVID.
Additional file 2: Distribution of TFBSs and EREs in promoters of
genes that contain predicted EREs. Details of gene IDs and positions
on promoters where TFBSs and EREs were predicted to have binding
sites.
Additional file 3: TFs common and unique to gene groups 1 and 3.
This file contains list of genes that were found to be common and
unique to groups 1 and 3.
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Page 10 of 13Additional file 4: TFs common and unique to gene groups
‘experimentally controlled genes’ and 3. This file contains list of genes
that were found to be common and unique to groups 3 and
‘experimentally controlled genes’.
Additional file 5: TFs common and unique to gene groups
‘experimentally controlled genes’ and 4. This file contains list of genes
that were found to be common and unique to groups 4 and
‘experimentally controlled genes’.
Additional file 6: TFs with ranks for a set of 323 genes. The list of all
TFs with ranks based on number of genes they potentially control from
full set of 323 genes.
Additional file 7: Details of primary source of the data for partly
validating the biomarkers using CleanEx database. Description of
previously published study material that was used for partial validation of
biomarkers identified in the current study.
Additional file 8: Functional categorization as identified using
Gene/Gene Set overlap matrix with 17 TFs identified as biomarkers
for full set of OC genes. The graphical view is a matrix of collections of
gene sets, where each colored entry indicates that the two gene sets
have a statistically significant overlap. Overlap between gene and gene
sets were prominent for cell cycle associated TFs as observed for the first
two rows from E2F1, E2F3-4 and TFDP-1 genes). Functional relevance of
top ranked 17 biomarkers identified for full set of 323 OC genes in the
present investigation.
Additional file 9: Functional categorization as identified using
Gene/Gene Set overlap matrix with 17 TFs identified as biomarkers
for estrogen-controlled sub-set of 77 OC genes. The graphical view is
a matrix of collections of gene sets, where each colored entry indicates
that the two gene sets have a statistically significant overlap. Overlap
between gene and gene sets were prominent for cell cycle associated
TFs. Functional relevance of top ranked 17 biomarkers identified for
estrogen-controlled sub-set of 77 OC genes in the present investigation.
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